MedTrace Logo

Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users

NCT00977249 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2009-09-15

No results posted yet for this study

Summary

Primary aim: Will varenicline be better than placebo to get long-term users of NRT to stop?

Secondary aim: To assess in details some side effects of varenicline i.e. nausea and abnormal dreams.

Conditions

  • Tobacco Dependence

Interventions

BEHAVIORAL

support and visits

visits at weeks 0,2,4,6,9 and 12 and 12 months

DRUG

varenicline

DRUG

placebo

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Principal Investigators

  • Philip Tønnesen, M.D. · Gentofte Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00977249 on ClinicalTrials.gov